AstraZeneca’s MedImmune subsidiary has reached an agreement with US-based pharmaceutical major Pfizer for the potential cancer treatment tremelimumab.

MedImmune will assume global development rights to the CTLA-4 monoclonal antibody, whereas Pfizer will retain the rights to use the drug alongside combination therapies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

MedImmune Research and Development head Bahija Jallal said: "Adding another immunotherapeutic approach to our oncology pipeline… exemplifies our continued commitment to embracing this new era of cancer."

Tremelimumab has had something of a chequered past, with Pfizer discontinuing a late-stage trial of the drug in 2008 following a review of interim data that showed the drug would not out-perform standard chemotherapy.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now